The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
SARS-CoV-2 Seroconversion
Timeframe: Between baseline and 2 weeks post the second dose
Influenza Seroconversion
Timeframe: Between baseline and 2 weeks post the second dose
SARS-CoV-2 Seroprotection
Timeframe: Between baseline and 2 weeks post the second dose
Influenza Seroprotection
Timeframe: Between baseline and 2 weeks post the second dose
SARS-CoV-2 Geometric mean titer fold change
Timeframe: Between baseline and 2 weeks post the second dose
Influenza geometric mean titer fold change
Timeframe: Between baseline and 2 weeks post the second dose
Safety assessment 1
Timeframe: Between time of administration of first dose and through study completion, an average of 10 months
Safety assessment 2
Timeframe: Between time of administration of first dose and through study completion, an average of 10 months
SARS-CoV-2 infection
Timeframe: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months
Influenza infection
Timeframe: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months